View COMPASS Pathways Plc Sponsored ADR CMPS stock quote prices, financial information, real-time forecasts, and company news from CNN.

Is CMPS a good stock to buy? We came across a bullish thesis on COMPASS Pathways plc on BioEquity Watch’s Substack. In this ...

Compass Pathways (NASDAQ: CMPS) is not your typical healthcare company. The London-based clinical-stage biopharma is developing therapies for various forms of depression that center around psilocybin, ...

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways ...

Today, the biotechnology sector is witnessing a significant rally, with Compass Pathways (NASDAQ:CMPS) leading the charge. As the company nears the finish line for its Phase 3 clinical trials, a ...

A White House Executive Order over the weekend has some healthcare company stocks soaring today. One big winner is Compass Pathways (NASDAQ: CMPS). Shares of the biotechnology company rocketed more ...

Compass Pathways (NASDAQ:CMPS) shares rose 14% after it reported first quarter results that topped expectations and showed continued regulatory progress for its lead therapy COMP360 in ...

This article was originally published on PSYCH and appears here with permission. UK-based COMPASS Pathways (NASDAQ:CMPS) recently published data from its Phase IIb trials, with COMP360 psilocybin ...

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways ...

While about 100 clinical trials focused on psychedelic compounds are chugging along in the regulatory pathway to examine the potential the drugs have to treat illnesses like depression and alcoholism, ...